Results 81 to 90 of about 10,873 (203)

Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study

, 2011
Introduction: We assessed the additional effects of eplerenone to angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on 24-h blood pressure (BP) level, fibrinolytic activity, and cardiovascular protection in ...
Kazuyuki Shimada, Yuichiro Yano, Satoshi Hoshide, Masahiko Nagata, Kouji Sasaki, Yoshimasa Kanemaru, Kazuomi Kario, Noboru Tamaki   +7 more
core   +1 more source

Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?

, 2009
Aims Aldosterone antagonism reduces cardiovascular morbidity and mortality in patients with left ventricular (LV) systolic dysfunction and heart failure or diabetes after acute myocardial infarction (AMI). The mechanism of this effect is unclear.
Ford, I., Weir, R.A.P., Petrie, C.J., Wagner, G.S., McMurray, J.J.V., Mark, P.B., Ng, L.L., Squire, I.B., Clements, S., Steedman, T., Galen S. Wagner, John J.V. McMurray, Henry J. Dargie, Tracey Steedman, Robin A.P. Weir, Patrick B. Mark, Leong L. Ng, Colin J. Petrie, Ian Ford, Iain B. Squire, Suzanne Clements   +20 more
core   +1 more source

Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia [PDF]

, 2017
Aims: Although hypokalaemia is common among patients with heart failure (HF), the prognostic significance of baseline hypokalaemia and hypokalaemia during follow-up in HF patients receiving a mineralocorticoid receptor antagonist (MRA) remains ...
Rossignol, Patrick, Swedberg, Karl, Sean Spanyers, Lamiral, Zohra, Renaud Fay, Faiez Zannad, Zannad, Faiez, John Vincent, Bakris, George, Solomon, Scott D., Scott D. Solomon, Zohra Lamiral, Girerd, Nicolas, Henry Krum, Vincent, John, Nicolas Girerd, van Veldhuisen, Dirk J., Brian Claggett, John J.V. McMurray, Fay, Renaud, Karl Swedberg, Bertram Pitt, Krum, Henry, George Bakris, Claggett, Brian, McMurray, John J.V., Harry Shi, McMurray, John J. V., Shi, Harry, Orly Vardeny, Dirk J. van Veldhuisen, Vardeny, Orly, Spanyers, Sean, Pitt, Bertram, Patrick Rossignol, Swedberg, Karl,   +35 more
core   +1 more source

New Clinical Aspects of Eplerenone Use in Clinical Practice

Рациональная фармакотерапия в кардиологии, 2018
The problem of the discrepancy between convincing evidences of the effectiveness of the use of mineralocorticoid receptor antagonists in patients with heart failure with reduced left ventricular ejection fraction and insufficiently frequent their use in ...
S. R. Gilyarevskiy, N. G. Bendeliani, M. V. Golshmid, I. M. Kuzmina   +3 more
doaj   +1 more source

A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy

Scientific Reports, 2017
Aldosterone antagonists slow the progression of chronic kidney disease (CKD), but their use is limited by hyperkalemia, especially when associated with RAS inhibitors.
Clarice K. Fujihara, M. C. Kowala, M. D. Breyer, Claudia R. Sena, Mariliza V. Rodrigues, Simone C. A. Arias, Camilla Fanelli, Denise M. Malheiros, P. K. Jadhav, Chahrzad Montrose-Rafizadeh, Jose E. Krieger, Roberto Zatz   +11 more
doaj   +1 more source

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

Orphanet Journal of Rare Diseases, 2017
Background Cardiomyopathy is a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). We recently showed in a 12-month double-blind randomized controlled trial that adding eplerenone to background medical therapy was ...
Subha V. Raman, Kan N. Hor, Wojciech Mazur, Xin He, John T. Kissel, Suzanne Smart, Beth McCarthy, Sharon L. Roble, Linda H. Cripe   +8 more
doaj   +1 more source

Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance

, 2017
Obesity-associated activation of the renin-angiotensin-aldosterone system is implicated in the pathogenesis of insulin resistance; however, influences of mineralocorticoid receptor (MR) inhibition remain unclear.
Akari Ishikawa, Hiroshi Tsuneki, Hiroe Honda, Yoko Ishii, Yasuhiro Onogi, Hayate Hasegawa, Yusuke Aruga, Kiyoshi Takatsu, Eri Watanabe, Yuto Nakamura, Masakiyo Sasahara, Toshiyasu Sasaoka, Tsutomu Wada, Yoshinori Nagai, Daisuke Koya   +14 more
core   +1 more source

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure

Health Technology Assessment, 2010
Background: Two aldosterone inhibitors are currently licensed for heart failure (HF) in the UK: spironolactone and eplerenone. Recent clinical guidelines recommend eplerenone after an acute myocardial infarction (MI) for patients with symptoms and/or ...
C McKenna, J Burch, S Suekarran, S Walker, A Bakhai, K Witte, M Harden, K Wright, N Woolacott, P Lorgelly, L Fenwick, S Palmer   +11 more
doaj   +1 more source

Eplerenone as a novel treatment for persistent subretinal fluid following retinal detachment surgery

American Journal of Ophthalmology Case Reports, 2018
Purpose: To describe the clinical course of a patient with persistent subretinal fluid (SRF) after primary scleral buckle surgery for a rhegmatogenous retinal detachment (RRD) repair who was subsequently treated with oral eplerenone for resolution of SRF.
Arezu Haghighi, Jiun Do, Hossein Ameri
doaj   +1 more source

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

Vascular Health and Risk Management, 2018
Mireille Fernet,1 Bruce Beckerman,2 Paula Abreu,2 Katharina Lins,3 John Vincent,2 Ellen Burgess4 1Department of Medical Affairs, Pfizer Canada Inc., Kirkland, QC, Canada; 2Department of Clinical Affairs, Pfizer Inc., New York, NY, USA; 3Department ...
Fernet M, Beckerman B, Abreu P, Lins K, Vincent J, Burgess E   +5 more
doaj